Keyword

bendamustine

Description: Bendamustine is an alkylating chemotherapy drug used to treat certain blood cancers, including non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Primary topic: Lymphoma Diagnosis and Treatment (42%)

Wikidata ID: wiki/Q425745

OpenAlex ID: keywords/bendamustine

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

2013 · Mathias J Rummel, Norbert Niederle, et al. · The Lancet · 1,514

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

2018 · John F. Seymour, Thomas J. Kipps, et al. · New England Journal of Medicine · 939

PDF

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

2019 · Laurie H. Sehn, Alex F. Herrera, et al. · Journal of Clinical Oncology · 776

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

2016 · Barbara Eichhorst, Anna-Maria Fink, et al. · The Lancet Oncology · 627

Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting

2019 · Ulrich Jäger, Wilma Barcellini, et al. · Blood Reviews · 565

The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

2011 · Julia Hoellenriegel, Sarah A. Meadows, et al. · Blood · 549

Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia

2009 · Wolfgang U. Knauf, Toshko Lissichkov, et al. · Journal of Clinical Oncology · 444

PDF

Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma

2005 · Mathias J. Rummel, Salah E. Al-Batran, et al. · Journal of Clinical Oncology · 441

PDF

Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

2012 · Kirsten Fischer, Paula Cramer, et al. · Journal of Clinical Oncology · 433

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

2015 · Asher Chanan-Khan, Paula Cramer, et al. · The Lancet Oncology · 415

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

2020 · Carlos A. Ramos, Natalie S. Grover, et al. · Journal of Clinical Oncology · 388

Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

2011 · Kirsten Fischer, Paula Cramer, et al. · Journal of Clinical Oncology · 379

Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents

2008 · Lorenzo M. Leoni, Brandi Bailey, et al. · Clinical Cancer Research · 369

Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma

2008 · K. Sue Robinson, Michael E. Williams, et al. · Journal of Clinical Oncology · 353

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2020 · E. Zucca, L. Arcaini, et al. · Annals of Oncology · 351

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

2016 · Laurie H Sehn, Neil Chua, et al. · The Lancet Oncology · 350

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

2022 · Michael Wang, Javier Munoz, et al. · Journal of Clinical Oncology · 331

Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study

2008 · Jonathan W. Friedberg, Philip Cohen, et al. · Journal of Clinical Oncology · 296

PDF

Postibrutinib outcomes in patients with mantle cell lymphoma

2016 · Peter Martin, Kami Maddocks, et al. · Blood · 294

PDF

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

2022 · Constantine S Tam, Jennifer R Brown, et al. · The Lancet Oncology · 293

How I treat Waldenström macroglobulinemia

2015 · Steven P. Treon · Blood · 288

PDF

Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment

2017 · Michael Hallek · American Journal of Hematology · 282

PDF

Mantle Cell Lymphoma

2016 · Chan Yoon Cheah, John F. Seymour, et al. · Journal of Clinical Oncology · 270

Bendamustine: Rebirth of an Old Drug

2009 · Bruce D. Cheson, Mathias J. Rummel · Journal of Clinical Oncology · 267

Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment

2015 · Michael Hallek · American Journal of Hematology · 264

Works count: 4,751

Citation count: 50,220